Blood Culture Identification (BCID) Panels

GenMark’s ePlex® Blood Culture Identification (BCID) Panels provide the broadest coverage of organisms that can lead to sepsis along with their resistance genes.

All BCID Panels Now FDA Cleared

VIEW SYSTEM
PRODUCT LITERATURE

Early Identification Helps Improve Patient Outcomes

It is estimated that 20-30% of patients receive ineffective initial antibiotic therapy and the mortality rate for these patients increases up to 7.6% for every hour effective antibiotics are delayed.[1][2]

The ePlex BCID Panels aid clinicians in the identification of bacterial and fungal organisms as well as antibiotic resistance genes within approximately 1.5 hours of blood bottle positivity, allowing treatment decisions to occur days earlier than with conventional methods. Unique ePlex solutions, like the ePlex Templated Comments Module, help to improve antimicrobial stewardship and optimize patient care.

The Most Comprehensive Molecular Blood Culture Panels

The ePlex BCID Panels offer the broadest coverage of organisms and resistance markers that can lead to sepsis, including anaerobes and multidrug resistant organisms (MDRO), as well as common and emerging fungal pathogens. The ePlex BCID Fungal Pathogen (FP) Panel is the only multiplex molecular panel to include Candida auris, an MDRO of increasing prevalence.[3]

Blood Culture Identification Test Inclusivity based on Potula et al. Inclusivity based on GenMark Clinical Study Database
ePlex BCID (GP, GN and FP) Panels 99.6% 94.0%

Blood culture panel target inclusivity based on prevalence of organisms that cause blood stream infections in the United States (Potula et. al at Temple University Hospital, n = 2,569)2 and GenMark’s prospective clinical trial database (n=1111 from 10 US clinical study sites).

Resistance Genes Inform Rapid Clinical Decision Making

The ePlex BCID Panels include 4 gram-positive and 10 gram-negative resistance genes that can be detected days earlier than conventional antimicrobial susceptibility tests (AST), enabling earlier escalation of therapy for resistant organisms or de-escalation of empirical antimicrobials. Rapid detection of antibiotic resistance genes when applied with local epidemiology of resistance, has been shown to agree 100% with subsequent phenotypic susceptibility testing, allowing for recommendation of a targeted therapy earlier.[5]

Rapidly Rule-Out Blood Culture Contamination

Published studies show that up to 30% of positive blood cultures may be due to contaminants which can result in continuation of unnecessary antibiotics[5]. ePlex BCID Panels are designed to allow labs to more rapidly differentiate a contaminant from a true infection, enabling rapid de-escalation and discharge of patients with a bloodstream infection 2-3 days earlier than conventional methods.

BACTERIAL TARGETS

  • Bacillus subtilis group
  • Corynebacterium
  • Cutibacterium acnes
  • Lactobacillus group
  • Micrococcus
  • Staphylococcus and Staphylococcus epidermis (CoNS)
ePlex BCID-GP Panel ePlex BCID-GN Panel ePlex BCID-FP Panel
Gram-Positive Organisms Gram-Negative Organisms Fungal Organisms
Bacillus cereus group Acinetobacter baumannii Candida albicans
Bacillus subtilis group Bacteroides fragilis Candida auris
Corynebacterium Citrobacter Candida dubliniensis
Cutibacterium acnes  Cronobacter sakazakii Candida famata
(Propionibacterium acnes) Enterobacter (non-cloacae complex) Candida glabrata
Enterococcus Enterobacter cloacae complex Candida guilliermondii
Enterococcus faecalis Escherichia coli Candida kefyr
Enterococcus faecium Fusobacterium nucleatum Candida krusei
Lactobacillus Fusobacterium necrophorum Candida lusitaniae
Listeria Haemophilus influenzae Candida parapsilosis
Listeria monocytogenes Klebsiella oxytoca Candida tropicalis
Micrococcus Klebsiella pneumoniae group Cryptococcus gattii
Staphylococcus Morganella morganii Cryptococcus neoformans
Staphylococcus aureus Neisseria meningitidis Fusarium
Staphylococcus epidermidis Proteus Rhodotorula
Staphylococcus lugdunensis Proteus mirabilis
Streptococcus Pseudomonas aeruginosa
Streptococcus agalactiae (GBS) Salmonella
Streptococcus anginosus group Serratia
Streptococcus pneumoniae Serratia marcescens
Streptococcus pyogenes (GAS) Stenotrophomonas maltophilia
Resistance Genes Resistance Genes
mecA CTX-M
mecC IMP
vanA KPC
vanB NDM
OXA (OXA-23 and OXA-48)
VIM
Pan Targets Pan Targets
Pan Gram-Negative Pan Gram-Positive
Pan Candida Pan Candida

“Delivering definitive identification with resistance markers can aid the clinician’s decision on more targeted antimicrobial therapy sooner than conventional methods.”

Maria Malloy, Surveillance Scientist, National HCAI and AMR Response Team, Galway University Hospital, Ireland

“ePlex Panels have significantly changed the way we deal with blood cultures.  The medical laboratory scientists are happy with its ease of use and hands-on time per test, and we can provide clinicians more detailed information much sooner – within a couple hours of a positive blood culture, rather than days.”

Dr. Cathal Collins, Cavan General Hospital, Ireland

To learn more about the Blood Culture Identification (BCID) Panels or to schedule a demonstration, contact us at 1.800.373.6767 or email us.

[1] IDSA: Better Tests Better Care, The Promise of Next Generation Diagnostics. 
[2] Kumar, et al. (2006) Crit Care Med. 34 (6):1589-1596
[3] Singh, N. (2001) Clin Infect Dis, 33(10):1692-1696
[4] Detection rate based on panel inclusivity only, not a sensitivity/performance claim
[5] Rödel, et. al. (2016), Diag Micro and Inf Dis, 84:252-257
[6] Murray, P. et. al. (2012), Crit Care Med,Current Approaches to the Diagnosis of Bacterial and Fungal Bloodstream Infections for the ICU.